Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
51
CTMX Quote, Financials, Valuation and Earnings
Last price:
$3.96
Seasonality move
:
11.81%
Day range:
$3.92 - $4.09
52-week range:
$0.40 - $4.62
Dividend yield:
0%
P/E ratio:
9.45x
P/S ratio:
4.01x
P/B ratio:
6.23x
Volume:
929.8K
Avg. volume:
3.2M
1-year change:
240.52%
Market cap:
$669.3M
Revenue:
$138.1M
EPS (TTM):
$0.42
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$11.5M | -$0.04 | -80.27% | -23% | $7.07 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$780.4M | $0.31 | 11.55% | 43.52% | $88.48 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$3.95 | $7.07 | $669.3M | 9.45x | $0.00 | 0% | 4.01x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$53.40 | $88.48 | $10.3B | 20.01x | $0.00 | 0% | 3.38x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $727K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
4.95% | 11.461 | 1.06% | 3.54x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.764 | 5.87% | 2.84x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CTMX
CytomX Therapeutics, Inc.
|
$5.8M | -$15.9M | 52.07% | 61.33% | -266.11% | -$15.4M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
CytomX Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CTMX or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of -3.91%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About CTMX or BMRN?
CytomX Therapeutics, Inc. has a consensus price target of $7.07, signalling upside risk potential of 79.02%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.48 which suggests that it could grow by 65.69%. Given that CytomX Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe CytomX Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 1 0 BMRNBioMarin Pharmaceutical, Inc.15 6 0 -
Is CTMX or BMRN More Risky?
CytomX Therapeutics, Inc. has a beta of 2.371, which suggesting that the stock is 137.13% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.071%.
-
Which is a Better Dividend Stock CTMX or BMRN?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or BMRN?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. CytomX Therapeutics, Inc.'s net income of -$14.2M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 9.45x while BioMarin Pharmaceutical, Inc.'s PE ratio is 20.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 4.01x versus 3.38x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.4.01x 9.45x $6M -$14.2M BMRNBioMarin Pharmaceutical, Inc.3.38x 20.01x $786.8M -$30.7M
-
Which has Higher Returns CTMX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of -255.85%. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CTMX or NBY?
CytomX Therapeutics, Inc. has a consensus price target of $7.07, signalling upside risk potential of 79.02%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that CytomX Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe CytomX Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CTMX or NBY More Risky?
CytomX Therapeutics, Inc. has a beta of 2.371, which suggesting that the stock is 137.13% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CTMX or NBY?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or NBY?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 9.45x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 4.01x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.4.01x 9.45x $6M -$14.2M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns CTMX or OGEN?
Oragenics, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of --. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About CTMX or OGEN?
CytomX Therapeutics, Inc. has a consensus price target of $7.07, signalling upside risk potential of 79.02%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that Oragenics, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 1 0 OGENOragenics, Inc.1 0 0 -
Is CTMX or OGEN More Risky?
CytomX Therapeutics, Inc. has a beta of 2.371, which suggesting that the stock is 137.13% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock CTMX or OGEN?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or OGEN?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than Oragenics, Inc. quarterly revenues of --. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 9.45x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 4.01x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.4.01x 9.45x $6M -$14.2M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns CTMX or PTN?
Palatin Technologies has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of --. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M PTNPalatin Technologies-- -- -- -
What do Analysts Say About CTMX or PTN?
CytomX Therapeutics, Inc. has a consensus price target of $7.07, signalling upside risk potential of 79.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than CytomX Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 1 0 PTNPalatin Technologies0 0 0 -
Is CTMX or PTN More Risky?
CytomX Therapeutics, Inc. has a beta of 2.371, which suggesting that the stock is 137.13% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock CTMX or PTN?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or PTN?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than Palatin Technologies quarterly revenues of --. CytomX Therapeutics, Inc.'s net income of -$14.2M is higher than Palatin Technologies's net income of --. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 9.45x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 4.01x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.4.01x 9.45x $6M -$14.2M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns CTMX or TOVX?
Theriva Biologics, Inc. has a net margin of -238.62% compared to CytomX Therapeutics, Inc.'s net margin of --. CytomX Therapeutics, Inc.'s return on equity of 61.33% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital CTMXCytomX Therapeutics, Inc.97.75% -$0.09 $113M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About CTMX or TOVX?
CytomX Therapeutics, Inc. has a consensus price target of $7.07, signalling upside risk potential of 79.02%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than CytomX Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than CytomX Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CTMXCytomX Therapeutics, Inc.5 1 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is CTMX or TOVX More Risky?
CytomX Therapeutics, Inc. has a beta of 2.371, which suggesting that the stock is 137.13% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock CTMX or TOVX?
CytomX Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytomX Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CTMX or TOVX?
CytomX Therapeutics, Inc. quarterly revenues are $6M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. CytomX Therapeutics, Inc.'s net income of -$14.2M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, CytomX Therapeutics, Inc.'s price-to-earnings ratio is 9.45x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytomX Therapeutics, Inc. is 4.01x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CTMXCytomX Therapeutics, Inc.4.01x 9.45x $6M -$14.2M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
